Hospital
Community Hospital Group INC
Community Hospital Group INC was paid $71.47M by Medicaid between Jan 2018 and Nov 2024, across 384 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoCOMMUNITY HOSPITAL GROUP INC
EDISON, NJ 08820
EDISON, NJ 08820
33aNPI1659387975assigned 07/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$71.47M
24GClaims1,033,169
24DCodes billed384
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#25 of 93
Median peer was paid$30.60M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SMITH, RICHARD controls 13+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 255,363 | $18.47M | |
| 2019 | 262,002 | $17.84M | |
| 2020 | 212,835 | $14.22M | |
| 2021 | 291,134 | $20.16M | |
| 2022 | 11,092 | $785K | |
| 2023 | 199 | $1K | |
| 2024incomplete | 544 | $2K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 55,787 | 52,717 | $14.39M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 24,883 | 23,784 | $7.83M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 7.8% | 17,109 | 15,232 | $5.58M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 5.1% | 12,095 | 11,582 | $3.62M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 5.0% | 5,296 | 5,258 | $3.54M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.4% | 5,128 | 5,078 | $2.42M |
| G0378 | Hospital observation service, per hour | 3.1% | 6,163 | 5,442 | $2.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.7% | 5,635 | 5,463 | $1.91M |
| 93017 | 2.5% | 6,658 | 6,566 | $1.78M | |
| 93458 | 2.3% | 1,081 | 1,068 | $1.68M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 3,986 | 3,911 | $1.17M |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.5% | 3,422 | 2,103 | $1.06M |
372 more codes
| A0434 | Specialty care transport (sct) | 1.5% | 2,550 | $1.04M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.2% | 1,176 | $865K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 5,913 | $811K |
| A0425 | Ground mileage, per statute mile | 1.1% | 38,897 | $786K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 6,717 | $761K |
| OP250 | <1% | 43,430 | $675K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,710 | $614K |
| 29580 | <1% | 2,241 | $484K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,070 | $481K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,742 | $473K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,900 | $468K |
| OP370 | <1% | 2,495 | $463K | |
| 80053 | Comprehensive metabolic panel | <1% | 43,354 | $454K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 43,766 | $454K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12,646 | $430K |
| 29581 | <1% | 1,105 | $411K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,113 | $366K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,497 | $347K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 5,731 | $340K |
| OP272 | <1% | 10,991 | $318K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,625 | $285K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,420 | $281K |
| 76830 | Ultrasound, transvaginal | <1% | 1,916 | $271K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 672 | $261K |
| OP710 | <1% | 3,045 | $254K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 3,985 | $252K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,942 | $250K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,315 | $239K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,926 | $236K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,788 | $221K |
| 76801 | <1% | 1,898 | $213K | |
| 76642 | <1% | 1,435 | $204K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,160 | $202K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,624 | $196K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 6,965 | $183K |
| 93970 | <1% | 1,186 | $180K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,429 | $178K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,017 | $178K |
| 76641 | <1% | 1,064 | $177K | |
| A0433 | Advanced life support, level 2 (als 2) | <1% | 468 | $173K |
| OP258 | <1% | 19,613 | $167K | |
| 95953 | <1% | 222 | $159K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,027 | $158K |
| 93880 | <1% | 1,026 | $156K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,055 | $154K |
| 84484 | <1% | 16,396 | $154K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,029 | $145K |
| 70496 | <1% | 875 | $139K | |
| 72141 | <1% | 312 | $135K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,914 | $132K |
| 77066 | Tomosynthesis, mammo | <1% | 1,175 | $130K |
| 64483 | <1% | 173 | $130K | |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | <1% | 59 | $128K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,819 | $125K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,073 | $124K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,427 | $122K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,305 | $121K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,004 | $120K |
| 82962 | <1% | 10,984 | $116K | |
| 77080 | <1% | 811 | $116K | |
| 85610 | <1% | 20,069 | $111K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,093 | $111K |
| 85730 | <1% | 18,114 | $104K | |
| 95708 | <1% | 169 | $103K | |
| 73130 | <1% | 1,545 | $103K | |
| 93971 | <1% | 807 | $98K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,771 | $95K |
| 72110 | <1% | 1,482 | $95K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,385 | $95K |
| 85027 | <1% | 13,058 | $94K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,023 | $93K |
| 77065 | Tomosynthesis, mammo | <1% | 1,131 | $90K |
| 80061 | Lipid panel | <1% | 5,652 | $84K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 3,047 | $83K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,869 | $83K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,130 | $78K |
| 73630 | <1% | 1,803 | $78K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 4,368 | $76K |
| 73030 | <1% | 1,575 | $74K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 335 | $74K |
| 71250 | <1% | 569 | $70K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,676 | $67K |
| C1769 | Guide wire | <1% | 1,270 | $67K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,021 | $66K |
| 70498 | <1% | 744 | $65K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,419 | $65K |
| 76536 | <1% | 393 | $62K | |
| 95700 | <1% | 186 | $62K | |
| 73610 | <1% | 1,798 | $61K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 885 | $59K |
| 76820 | <1% | 458 | $56K | |
| 83605 | <1% | 7,412 | $55K | |
| 81025 | <1% | 17,598 | $55K | |
| 83735 | <1% | 6,851 | $55K | |
| 73562 | <1% | 1,246 | $54K | |
| 95957 | <1% | 177 | $53K | |
| 81003 | <1% | 16,869 | $52K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,664 | $49K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 206 | $49K |
| 87070 | <1% | 6,471 | $48K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 573 | $48K |
| 74018 | <1% | 2,115 | $47K | |
| 86900 | <1% | 5,177 | $47K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 267 | $47K |
| OP278 | <1% | 123 | $46K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,736 | $44K |
| OP379 | <1% | 1,042 | $43K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 62 | $43K |
| 87040 | <1% | 4,068 | $43K | |
| 96376 | <1% | 1,045 | $42K | |
| 83880 | <1% | 2,798 | $41K | |
| 84702 | <1% | 4,432 | $40K | |
| 87400 | <1% | 6,009 | $40K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,931 | $40K |
| 76770 | <1% | 393 | $39K | |
| 73564 | <1% | 786 | $38K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,290 | $38K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 99 | $38K |
| 86850 | <1% | 4,260 | $38K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 615 | $36K |
| 96367 | <1% | 736 | $36K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 30 | $36K |
| 72050 | <1% | 412 | $34K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,903 | $34K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 65 | $33K |
| 83690 | <1% | 9,094 | $33K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 435 | $33K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 831 | $32K |
| 0002A | <1% | 1,053 | $31K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,446 | $31K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 656 | $31K |
| 87088 | <1% | 4,846 | $31K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 623 | $31K |
| 81001 | <1% | 8,661 | $31K | |
| 87486 | <1% | 1,830 | $30K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,374 | $30K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,433 | $30K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 493 | $30K |
| OP279 | <1% | 11,066 | $29K | |
| 73110 | <1% | 968 | $28K | |
| 72100 | <1% | 482 | $28K | |
| 73502 | <1% | 882 | $28K | |
| 87581 | <1% | 1,830 | $28K | |
| J1245 | Injection, dipyridamole, per 10 mg | <1% | 2,536 | $27K |
| 0001A | <1% | 990 | $26K | |
| 86901 | <1% | 4,626 | $26K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,084 | $25K |
| 95811 | <1% | 24 | $25K | |
| 74019 | <1% | 1,308 | $25K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,459 | $24K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,072 | $24K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,714 | $24K |
| OP259 | <1% | 12,116 | $23K | |
| OP270 | <1% | 2,885 | $23K | |
| 95816 | <1% | 186 | $22K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,862 | $22K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 956 | $22K |
| 87186 | <1% | 2,602 | $22K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 558 | $22K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 175 | $22K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,626 | $22K |
| 82550 | <1% | 2,741 | $22K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,083 | $21K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 733 | $20K |
| 82607 | <1% | 1,555 | $20K | |
| 92083 | <1% | 273 | $20K | |
| 84100 | <1% | 3,294 | $19K | |
| 73140 | <1% | 494 | $19K | |
| 76775 | <1% | 192 | $19K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,248 | $18K |
| 86703 | <1% | 816 | $17K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,506 | $17K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 255 | $17K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,578 | $17K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,858 | $16K |
| 73590 | <1% | 515 | $16K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 691 | $16K |
| 72052 | <1% | 338 | $16K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 558 | $16K |
| 84439 | <1% | 1,292 | $16K | |
| 84145 | <1% | 1,046 | $15K | |
| 86140 | <1% | 4,864 | $15K | |
| 80047 | <1% | 4,114 | $15K | |
| 70486 | <1% | 107 | $15K | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 2,052 | $15K |
| 36430 | <1% | 443 | $15K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 330 | $15K |
| 70544 | <1% | 69 | $14K | |
| 12011 | <1% | 84 | $13K | |
| 19083 | <1% | 12 | $13K | |
| 82728 | <1% | 1,109 | $13K | |
| 73080 | <1% | 517 | $13K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 503 | $13K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 166 | $13K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,661 | $13K |
| 87420 | <1% | 2,228 | $12K | |
| 97161 | <1% | 839 | $12K | |
| 64493 | <1% | 12 | $12K | |
| 87660 | <1% | 478 | $12K | |
| 87480 | <1% | 478 | $12K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,002 | $11K |
| 87510 | <1% | 477 | $11K | |
| 85379 | <1% | 2,383 | $11K | |
| 90715 | <1% | 1,420 | $11K | |
| 74022 | <1% | 330 | $11K | |
| 87340 | <1% | 843 | $11K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,469 | $10K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 937 | $10K |
| 87077 | <1% | 1,190 | $10K | |
| 84480 | <1% | 608 | $10K | |
| 88304 | <1% | 424 | $9K | |
| 71101 | <1% | 221 | $9K | |
| 82746 | <1% | 798 | $9K | |
| 76813 | <1% | 94 | $9K | |
| 73090 | <1% | 344 | $9K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 289 | $9K |
| 12001 | <1% | 81 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,445 | $9K |
| 76818 | <1% | 29 | $8K | |
| 93976 | <1% | 82 | $8K | |
| 82150 | <1% | 1,926 | $8K | |
| 76870 | <1% | 96 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,520 | $7K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 20 | $7K |
| 81002 | <1% | 4,120 | $7K | |
| 76821 | <1% | 61 | $7K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $6K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 404 | $6K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 385 | $6K |
| 80177 | <1% | 351 | $6K | |
| 83550 | <1% | 831 | $6K | |
| 85651 | <1% | 657 | $6K | |
| 83540 | <1% | 916 | $6K | |
| 62370 | <1% | 39 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,934 | $5K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 120 | $5K |
| 82248 | <1% | 665 | $5K | |
| 84550 | <1% | 1,227 | $5K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,339 | $5K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,986 | $5K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,756 | $5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,970 | $5K |
| 72070 | <1% | 91 | $5K | |
| 82077 | <1% | 902 | $5K | |
| 86769 | <1% | 218 | $5K | |
| 86920 | <1% | 313 | $4K | |
| 85652 | <1% | 1,535 | $4K | |
| 84436 | <1% | 424 | $4K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,096 | $4K |
| 82247 | <1% | 551 | $4K | |
| 82803 | <1% | 289 | $4K | |
| 80076 | <1% | 753 | $4K | |
| 86922 | <1% | 308 | $4K | |
| 86921 | <1% | 308 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 977 | $4K |
| 76937 | <1% | 135 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 619 | $3K |
| 0004A | <1% | 90 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,188 | $3K |
| 97602 | <1% | 83 | $3K | |
| 86803 | <1% | 206 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,649 | $3K |
| 80143 | <1% | 582 | $3K | |
| 51701 | <1% | 58 | $3K | |
| 0031A | <1% | 100 | $3K | |
| 80179 | <1% | 579 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 128 | $3K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 441 | $3K |
| 59025 | Fetal non-stress test | <1% | 26 | $2K |
| 94760 | <1% | 187 | $2K | |
| 86593 | <1% | 505 | $2K | |
| 85014 | <1% | 2,513 | $2K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 465 | $2K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 399 | $2K |
| 82105 | <1% | 139 | $2K | |
| 87205 | <1% | 56 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 567 | $2K |
| 86592 | <1% | 511 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,896 | $2K |
| 92133 | <1% | 75 | $2K | |
| J3490 | Unclassified drugs | <1% | 1,603 | $2K |
| 82043 | <1% | 472 | $2K | |
| 0064A | <1% | 55 | $2K | |
| 73560 | <1% | 31 | $2K | |
| 86336 | <1% | 32 | $2K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 51 | $2K |
| 82977 | <1% | 305 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 813 | $2K |
| 72040 | <1% | 15 | $2K | |
| 73552 | <1% | 51 | $1K | |
| 93975 | <1% | 12 | $1K | |
| 84153 | <1% | 95 | $1K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 14 | $1K |
| OP229 | <1% | 26 | $1K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 187 | $1K |
| 80074 | <1% | 26 | $1K | |
| 82677 | <1% | 32 | $1K | |
| 95874 | <1% | 102 | $912.22 | |
| 86762 | <1% | 123 | $901.76 | |
| 86308 | <1% | 202 | $878.04 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 662 | $875.35 |
| 80164 | <1% | 43 | $828.29 | |
| 76000 | <1% | 15 | $826.25 | |
| G0008 | Administration of influenza virus vaccine | <1% | 31 | $818.99 |
| 94200 | <1% | 13 | $732.12 | |
| 88312 | <1% | 31 | $718.48 | |
| J1815 | Injection, insulin, per 5 units | <1% | 27 | $675.83 |
| 72072 | <1% | 14 | $655.52 | |
| 94729 | <1% | 15 | $644.84 | |
| 90686 | <1% | 27 | $596.16 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 499 | $593.30 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 396 | $566.91 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 310 | $564.83 |
| 86618 | <1% | 31 | $550.09 | |
| 0071A | <1% | 13 | $483.12 | |
| 29125 | <1% | 12 | $479.05 | |
| 94727 | <1% | 14 | $468.24 | |
| 83615 | <1% | 125 | $446.36 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 354 | $437.33 |
| 86038 | <1% | 35 | $360.30 | |
| 29130 | <1% | 13 | $356.52 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 389 | $350.77 |
| 72131 | <1% | 12 | $330.33 | |
| 87045 | <1% | 29 | $313.37 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 151 | $307.12 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 29 | $295.25 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 193 | $280.58 |
| 87427 | <1% | 38 | $275.93 | |
| G1001 | Clinical decision support mechanism evicore, as defined by the medicare appropriate use criteria program | <1% | 20 | $254.64 |
| 73060 | <1% | 31 | $253.73 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 117 | $242.53 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 16 | $232.16 |
| 85045 | <1% | 101 | $201.74 | |
| 97162 | <1% | 31 | $201.67 | |
| 97165 | <1% | 12 | $171.98 | |
| 85018 | <1% | 56 | $170.24 | |
| 82947 | <1% | 26 | $167.76 | |
| 91300 | <1% | 2,031 | $164.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 65 | $162.94 |
| 83020 | <1% | 28 | $159.96 | |
| 80197 | <1% | 17 | $147.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,129 | $143.77 |
| 97116 | <1% | 92 | $136.79 | |
| 36600 | <1% | 32 | $136.48 | |
| 86706 | <1% | 12 | $124.56 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 13 | $106.57 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 580 | $94.76 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 79 | $88.59 |
| 85378 | <1% | 26 | $82.85 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 254 | $80.28 |
| 86923 | <1% | 15 | $79.82 | |
| 99397 | <1% | 43 | $72.75 | |
| 84520 | <1% | 12 | $61.03 | |
| J3590 | Unclassified biologics | <1% | 231 | $59.62 |
| 82950 | <1% | 13 | $59.43 | |
| 82565 | <1% | 14 | $58.29 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 15 | $58.15 |
| OP637 | <1% | 1,075 | $55.03 | |
| G9035 | Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project) | <1% | 18 | $48.80 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 18 | $44.82 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 107 | $38.31 |
| 64644 | <1% | 43 | $29.84 | |
| A4615 | Cannula, nasal | <1% | 16 | $26.84 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 91 | $18.93 |
| 85347 | <1% | 13 | $10.00 | |
| 92550 | <1% | 12 | $6.44 | |
| 91303 | <1% | 98 | $5.00 | |
| 91306 | <1% | 58 | $3.00 | |
| 91307 | <1% | 40 | $3.00 | |
| D0220 | Intraoral - periapical first radiographic image | 0% | 131 | $0.00 |
| D0140 | Limited oral evaluation - problem focused | 0% | 93 | $0.00 |
| 91301 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, RICHARD (SR VICE PRESIDENT, CFO)
| Provider | Location | Paid |
|---|---|---|
| Community Hospital Group INC | Edison, NJ | $5.80M |
| JFK Medical Associates PA | Neptune, NJ | $4.44M |
| Modern Dental Professionals-Smith PA | Pine Bluff, AR | $2.27M |
| Community Hospital Group INC | Edison, NJ | $928K |
| Community Hospital Group, INC | Edison, NJ | $627K |
| Community Hospital Group INC | Edison, NJ | $399K |
| Jamestown Internal Medicine P.C. | Jamestown, TN | $350K |
| Community Hospital Group INC | Edison, NJ | $99K |
| North Bay Family Medical Clinic, PA | Biloxi, MS | $76K |
| Pathology Associates of Sturdy Memorial Hospital INC | Attleboro, MA | $55K |
| Richard Colville Smith, M.D., INC. | Vista, CA | $46K |
| North Attleborough Public Schools | North Attleboro, MA | $30K |
| Community Hospital Group INC | Edison, NJ | $393.92 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.